Other Clinical Trial - INcreased Sun Exposure Without Pain In Research

See also
Status	Clinical Trial	Phase
Completed	`NCT01880983` - Mitoferrin-1 Expression in Erythropoietic Protoporphyria (Porphyria Rare Disease Clinical Research Consortium (RDCRC))
Withdrawn	`NCT01550705` - Effect of Isoniazid on Protoporphyrin Levels in Erythropoietic Protoporphyria	N/A
Completed	`NCT03520036` - Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria	Phase 2

See also

Status

Clinical Trial

Phase

Completed

NCT01880983 - Mitoferrin-1 Expression in Erythropoietic Protoporphyria (Porphyria Rare Disease Clinical Research Consortium (RDCRC))

Withdrawn

NCT01550705 - Effect of Isoniazid on Protoporphyrin Levels in Erythropoietic Protoporphyria

N/A

Completed

NCT03520036 - Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria

Phase 2

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT06144840
Study type	Interventional
Source	Mitsubishi Tanabe Pharma America Inc.
Contact	Clinical Trials Information Desk, To prevent mis-communication,
Phone	please email:
Email	information@mt-pharma-us.com
Status	Recruiting
Phase	Phase 3
Start date	December 11, 2023
Completion date	June 2026

INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP — INSPIRE

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms